Vaginal Atrophy Clinical Trial
Official title:
Perceived Effectiveness of the Vaginal Moisturizer Investigational Product Under Normal Conditions of Use.
Verified date | March 2024 |
Source | Herbarium Laboratorio Botanico Ltda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present research project aims to evaluate the perceived effectiveness of the product under investigation under normal conditions of use for 28 days, to defend the claims "High hydration power, relief of discomfort and improvement of vaginal tone."
Status | Not yet recruiting |
Enrollment | 45 |
Est. completion date | May 15, 2024 |
Est. primary completion date | May 7, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 25 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Age range between 25 and 70 years old. 2. Phototypes: I to IV, according to Fitzpatrick classification; 3. Sex: female 4. Intact skin in the evaluation region. 5. Participants complaining of vaginal dryness; 6. Agree to adhere to the study procedures and requirements: study time, return(s) to the laboratory to perform study procedures, home use of the investigational product, filling out the usage diary, not changing cosmetic habits during the study period . 7. Agree not to carry out dermatological or aesthetic treatments until the end of the study and agree not to use any products from the same category as the investigational product. 8. Signing of the Free and Informed Consent Form (TCLE). Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Skin marks in the experimental area that interfere with the assessment of possible skin reactions. 3. Active dermatoses (local or disseminated) that could interfere with the study results. 4. History of ineffectiveness, allergic reactions, irritation or intense sensation of discomfort to topical products: health products or medications. 5. Expected vaccination during the study or up to 3 weeks before the study; 6. Not taking vitamin A (acid and/or its derivatives orally or topically up to 1 month before the start of the study.) 7. Patients with immunodeficiencies. 8. History of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic conjunctivitis, etc.). 9. Use of non-steroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizers or immunosuppressants up to 2 weeks before the study (or considering depot corticosteroids, the interval should be 1 month before the selection). 10. Aesthetic or dermatological treatment up to 4 weeks before the study. 11. Hormonal treatments not stable in the last 3 months. 12. Hyperpigmentation associated with the use of drugs such as tetracyclines, phenothiazides or amiodarone. 13. Hyperpigmentation associated with photosensitivity. 14. People directly involved in carrying out this study and their families. 15. History of lack of adherence or unwillingness to adhere to the study protocol. 16. Any condition that, in the researcher's opinion, could compromise the study. 17. Be participating in another study in the same region of application. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Herbarium Laboratorio Botanico Ltda |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | evaluate the perceived effectiveness of the investigational product | The perceived efficacy of the subjective method will be evaluated by means of questionnaires answered by the research participants after the first use and 28 days of use of the investigational product using a rating scale. The results of this evaluation will be used to analyze the frequency of scores for each attribute evaluated. Based on the results of the evaluation of the product's efficacy, an analysis of the frequency of scores for each question evaluated. | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06136975 -
Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence
|
||
Recruiting |
NCT04081805 -
LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)
|
N/A | |
Completed |
NCT04039555 -
Clinical Study to Compare the Efficacy of Erbium-Yag Laser or CO2RE Intimate Laser With Sham (COER)
|
N/A | |
Active, not recruiting |
NCT02704741 -
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
|
N/A | |
Completed |
NCT01975129 -
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
|
Phase 2 | |
Completed |
NCT04735549 -
Vulvovaginal Atrophy Correction Using Neodymium Laser
|
N/A | |
Completed |
NCT04079218 -
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
|
Phase 4 | |
Completed |
NCT03063684 -
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus
|
N/A | |
Recruiting |
NCT05953090 -
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
|
N/A | |
Not yet recruiting |
NCT05483634 -
Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause
|
||
Completed |
NCT04717245 -
Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment
|
N/A | |
Completed |
NCT02937805 -
Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes
|
N/A | |
Completed |
NCT02967510 -
Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT02571127 -
Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.
|
Phase 4 | |
Completed |
NCT00238732 -
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
|
Phase 3 | |
Completed |
NCT02413008 -
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
|
Phase 2 | |
Completed |
NCT03493126 -
Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function
|
Phase 4 | |
Not yet recruiting |
NCT03238053 -
Laser Treatment of Genito-urinary Syndrome in Women
|
N/A | |
Terminated |
NCT01753102 -
Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
|
Phase 3 | |
Terminated |
NCT05627791 -
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
|
Phase 2/Phase 3 |